Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.97 USD
Change Today -0.1811 / -3.52%
Volume 12.3K
CFRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 11:44 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

contrafect corp (CFRX) Snapshot

Open
$5.12
Previous Close
$5.15
Day High
$5.12
Day Low
$4.92
52 Week High
04/15/15 - $6.24
52 Week Low
12/10/14 - $2.50
Market Cap
124.6M
Average Volume 10 Days
70.9K
EPS TTM
$-2.35
Shares Outstanding
25.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CONTRAFECT CORP (CFRX)

Related News

No related news articles were found.

contrafect corp (CFRX) Related Businessweek News

No Related Businessweek News Found

contrafect corp (CFRX) Details

ContraFect Corporation, a biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-sensitive or methicillin-resistant Staph aureus; and CF-404, a combination of human monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza. The company was founded in 2008 and is headquartered in Yonkers, New York.

21 Employees
Last Reported Date: 03/26/15
Founded in 2008

contrafect corp (CFRX) Top Compensated Officers

Chief Executive Officer, Principal Financial ...
Total Annual Compensation: $712.5K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $427.8K
Consultant
Total Annual Compensation: $380.9K
Compensation as of Fiscal Year 2014.

contrafect corp (CFRX) Key Developments

ContraFect Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2015; Provides Monthly Cash Flow Guidance for the Year 2015

ContraFect Corporation reported earnings results for the second quarter ended June 30, 2015. For the quarter, the company reported a net loss of $7.1 million, or $0.33 per share, compared to a net loss of $8.3 million, or $8.17 per share, in the comparable prior year period. The company provided monthly cash flow guidance for the year 2015. The company expects that net cash used to fund operations will continue at approximately $2 million per month.

ContraFect Corporation to Report Q2, 2015 Results on Aug 13, 2015

ContraFect Corporation announced that they will report Q2, 2015 results on Aug 13, 2015

ContraFect Corporation Announces Executive Appointments

ContraFect Corporation appointed Steven C. Gilman, PhD, to its Board of Directors where he will assume the role of Executive Chairman. Dr. Gilman was Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals, until its acquisition by Merck & Co. in January 2015. Sol Barer, PhD, will assume the title of Lead Independent Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CFRX:US $4.97 USD -0.1811

CFRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CFRX.
View Industry Companies
 

Industry Analysis

CFRX

Industry Average

Valuation CFRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CONTRAFECT CORP, please visit www.contrafect.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.